Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Paracetamol→

Paracetamol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
103-90-2
Molecular formula
C8H9NO2
Molecular weight
151.16 g/mol
Drug class
Analgesic and antipyreticp-aminophenol derivative
Mechanism of action
The precise mechanism is not fully established. Central mechanisms are considered important, including modulation of prostaglandin pathways and descending serotonergic/nitric-oxide-related pain signalling; antipyretic activity is associated with effects on central prostaglandin signalling in the hypothalamic thermoregulatory centre.
Indications / reported uses
  • Relief of mild-to-moderate pain, including headache, musculoskeletal pain and dental pain.
  • Reduction of fever.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/acetaminophen · https://www.ncbi.nlm.nih.gov/books/NBK560692/

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Paracetamol Environmental Risk Assessment (ERA) (the Paracetamol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.